Alcohol Use Disorder
Conditions
Keywords
alcohol use disorder, alcoholism, alcohol dependence, drinking alcohol
Brief summary
The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.
Interventions
Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
Sponsors
Study design
Eligibility
Inclusion criteria
Subjects must meet each one of the following inclusion criteria in order to be eligible for participation in the study: 1. Be at least 21 years of age. 2. Have a current (past 12 months) DSM-5 diagnosis of AUD. 3. Have a BAC by breathalyzer equal to 0.000 when s/he signed the informed consent document (either just prior to or immediately after signing consent). 4. Be seeking treatment for problems with alcohol. Additional will be evaluated in clinic.
Exclusion criteria
Evaluations will be conducted in clinic.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects With no Heavy Drinking Days (PSNHDD) | Weeks 22-25 | The primary objective of the study is to compare the efficacy of HORIZANT (gabapentin enacarbil) Extended-Release Tablets 600 mg twice daily (BID) with matched placebo on the primary alcohol consumption outcome endpoint, percentage of subjects with no heavy drinking days (PSNHDD) during the last 4 weeks of treatment, among patients with Alcohol Use Disorder (AUD). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects Abstinent From Alcohol (Key Secondary Endpoint) | Weeks 22-25 | Timeline Follow-back drinking data is used to calculate the % of subjects that report not drinking alcohol during weeks 22-25 |
| Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 1-level | Weeks 22-25 | Timeline Follow Back data is used to calculate the % of participants that decrease at least 1-level WHO drinking risk category. The WHO has developed a drinking risk categorical scale that can be used in a responder analysis approach to assess clinically relevant decreases in alcohol consumption (Aubin et al-2015). The WHO 1- and 2-level decrease endpoints are the percentage of subjects experiencing at least 1- and 2-level decrease in WHO levels of alcohol consumption, respectively, from the level at baseline (the period including the 28 days before screening) to the level during the last 4 weeks of the maintenance phase (Study Weeks 22-25). The WHO levels are as follows: Males Females Low Risk 1 to 40g 1 to 20g Medium Risk 41 to 60g 21 to 40g High Risk 61 to 100g 41 to 60g Very High Risk 101+g 61+g |
| Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 2-levels | Weeks 22-25 | Timeline Follow Back data is used to calculate the % of participants that decrease at least 1-level WHO drinking risk category. The WHO has developed a drinking risk categorical scale that can be used in a responder analysis approach to assess clinically relevant decreases in alcohol consumption (Aubin et al-2015). The WHO 1- and 2-level decrease endpoints are the percentage of subjects experiencing at least 1- and 2-level decrease in WHO levels of alcohol consumption, respectively, from the level at baseline (the period including the 28 days before screening) to the level during the last 4 weeks of the maintenance phase (Study Weeks 22-25). The WHO levels are as follows: Males Females Low Risk 1 to 40g 1 to 20g Medium Risk 41 to 60g 21 to 40g High Risk 61 to 100g 41 to 60g Very High Risk 101+g 61+g |
| Percentage of Days Abstinent Per Week | Weeks 22-25 | Timeline Follow Back daily drinking data used to calculate the % of days abstinent per week. |
| Percentage of Heavy Drinking Days Per Week | Weeks 22-25 | Timeline Follow Back data used to calculate the % of heavy drinking days per week. Heavy drinking is 4+ drinks per day for females and 5+ drinks per day for males |
| Weekly Mean Number of Drinks Per Week | Weeks 22-25 | Timeline Follow Back data used to calculate the weekly mean number of drinks per week |
| Weekly Mean Drinks Per Drinking Day | Weeks 22-25 | Timeline Follow Back daily drinking data used to calculate the weekly mean drinks per drinking day |
| Cigarettes Per Week Among Smokers | Weeks 22-25 | A quantity frequency interview of three questions to assess cigarette smoking behavior and other tobacco/nicotine containing products use during the study: 1) Over the past week, on how many days did you smoke cigarettes?, 2) On the days you smoked during the past week, how many cigarettes did you smoke on average?, and 3) Have you used any other tobacco or nicotine containing products besides cigarettes in the past week (e.g., cigars, cigarellos, pipes, bidis, or smokeless tobacco such as pan, chewing tobacco, or snuff, or nicotine replacement therapies such as patch or gum)?. |
| Alcohol Craving Score [Alcohol Craving Scale - Short Form (ACQ-SR-R)] | Weeks 24 and 26 | The ACQ-SR-R contains 12-items adapted from the 47-item ACQ-NOW developed by Singleton et al (1994) to assess craving for alcohol among alcohol users in the current context (right now). Each item has a 1 to 7 raw score (from strongly disagree to strongly agree). Items 3, 8, and 11 are reverse keyed. A general craving index is derived by summing all items and dividing by 12. Minimum score is 1 and maximum score is 7. Higher scores are indicative of higher craving. Mixed effects models as stated in Section 9.4.3 of the SAP will be generated for the total score and for the 4 subscales. Covariates for these models will be identified |
| Alcohol Related Consequences (ImBIBe) Score | Weeks 24 and 26 | ImBIBe is a 15-item questionnaire in which the subject responds on a 5-point scale (0-4) responses to questions on the consequences of alcohol use. This scale was adapted from the Drinker Inventory of Consequences questionnaire based on FDA recommendations on patient reported outcomes (Miller & Tonigen-1995). The potential range is 0-60. A higher score indicates a worse outcome. The questions are added together. A question that is missing is imputed with the average value of all other questions in the questionnaire.The total score is the sum of the individual item scores. Mixed effects models as stated in Section 9.4.3 will be generated for the total score. Covariates for these models will be identified |
| Pittsburgh Sleep Quality Index (PSQI) Score | Week 26 | The PSQI is a 19-item questionnaire assessing the subject's overall sleep experience in the past 30 days (Buysse et al-1989). The lower the overall score, the better the person sleeps. The tool has an adequate internal reliability, validity and consistency for clinical and community samples of the various populations. Range is (0-21); \>6 indicative of poor sleep quality. |
| Beck Anxiety Inventory (BAI) Score | Week 26 | The BAI consists of 21 questions about how the subject has been feeling in the last week, expressed as common symptoms of anxiety (such as numbness and tingling, sweating not due to heat, and fear of the worst happening). This inventory was designed to minimize the overlap with depression scales (Beck et al-1988).The BAI has a maximum score of 63. The standardized cutoffs for anxiety severity are: 0-7: minimal level of anxiety 8-15: mild anxiety 16-25: moderate anxiety 26-63: severe anxiety |
| Beck Depression Inventory - II | Week 26 | The BDI-II is a 21-item multiple choice questionnaire that is used for measuring the severity of depression (Beck et al-1966). Each item is scored on a scale value of 0 to 3. The standardized cutoffs for depression severity are: 0-13: minimal depression 14-19: mild depression 20-28: moderate depression 29-63: severe depression |
Countries
United States
Participant flow
Recruitment details
The study was a Phase 2, randomized, double-blind, placebo controlled, parallel-group 26-week treatment clinical trial. Candidates responded by telephone to advertisements at 10 academic sites in the US between June 2015 and February 2017.
Participants by arm
| Arm | Count |
|---|---|
| Sugar Pill Matching placebo, sugar pill
Placebo: Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day | 168 |
| Gabapentin Enacarbil 600 mg Gabapentin Enacarbil (Horizant)
gabapentin enacarbil: Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day | 170 |
| Total | 338 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 5 | 3 |
Baseline characteristics
| Characteristic | Sugar Pill | Total | Gabapentin Enacarbil |
|---|---|---|---|
| Age, Continuous | 49.4 years STANDARD_DEVIATION 11.4 | 50.1 years STANDARD_DEVIATION 10.8 | 50.7 years STANDARD_DEVIATION 10.3 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 18 Participants | 32 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 146 Participants | 296 Participants | 150 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants | 10 Participants | 6 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 3 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 28 Participants | 63 Participants | 35 Participants |
| Race (NIH/OMB) More than one race | 10 Participants | 19 Participants | 9 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 7 Participants | 5 Participants |
| Race (NIH/OMB) White | 126 Participants | 243 Participants | 117 Participants |
| Region of Enrollment United States | 168 Participants | 338 Participants | 170 Participants |
| Sex: Female, Male Female | 67 Participants | 115 Participants | 48 Participants |
| Sex: Female, Male Male | 101 Participants | 223 Participants | 122 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 168 | 1 / 170 |
| other Total, other adverse events | 155 / 168 | 157 / 170 |
| serious Total, serious adverse events | 6 / 168 | 8 / 170 |
Outcome results
Percentage of Subjects With no Heavy Drinking Days (PSNHDD)
The primary objective of the study is to compare the efficacy of HORIZANT (gabapentin enacarbil) Extended-Release Tablets 600 mg twice daily (BID) with matched placebo on the primary alcohol consumption outcome endpoint, percentage of subjects with no heavy drinking days (PSNHDD) during the last 4 weeks of treatment, among patients with Alcohol Use Disorder (AUD).
Time frame: Weeks 22-25
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Sugar Pill | Percentage of Subjects With no Heavy Drinking Days (PSNHDD) | 17.3 percentage of subjects with NHDD |
| Gabapentin Enacarbil | Percentage of Subjects With no Heavy Drinking Days (PSNHDD) | 24.1 percentage of subjects with NHDD |
Alcohol Craving Score [Alcohol Craving Scale - Short Form (ACQ-SR-R)]
The ACQ-SR-R contains 12-items adapted from the 47-item ACQ-NOW developed by Singleton et al (1994) to assess craving for alcohol among alcohol users in the current context (right now). Each item has a 1 to 7 raw score (from strongly disagree to strongly agree). Items 3, 8, and 11 are reverse keyed. A general craving index is derived by summing all items and dividing by 12. Minimum score is 1 and maximum score is 7. Higher scores are indicative of higher craving. Mixed effects models as stated in Section 9.4.3 of the SAP will be generated for the total score and for the 4 subscales. Covariates for these models will be identified
Time frame: Weeks 24 and 26
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Alcohol Craving Score [Alcohol Craving Scale - Short Form (ACQ-SR-R)] | 2.5 scores on a scale | Standard Error 0.1 |
| Gabapentin Enacarbil | Alcohol Craving Score [Alcohol Craving Scale - Short Form (ACQ-SR-R)] | 2.5 scores on a scale | Standard Error 0.1 |
Alcohol Related Consequences (ImBIBe) Score
ImBIBe is a 15-item questionnaire in which the subject responds on a 5-point scale (0-4) responses to questions on the consequences of alcohol use. This scale was adapted from the Drinker Inventory of Consequences questionnaire based on FDA recommendations on patient reported outcomes (Miller & Tonigen-1995). The potential range is 0-60. A higher score indicates a worse outcome. The questions are added together. A question that is missing is imputed with the average value of all other questions in the questionnaire.The total score is the sum of the individual item scores. Mixed effects models as stated in Section 9.4.3 will be generated for the total score. Covariates for these models will be identified
Time frame: Weeks 24 and 26
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Alcohol Related Consequences (ImBIBe) Score | 8.3 total score | Standard Error 0.7 |
| Gabapentin Enacarbil | Alcohol Related Consequences (ImBIBe) Score | 9.6 total score | Standard Error 0.7 |
Beck Anxiety Inventory (BAI) Score
The BAI consists of 21 questions about how the subject has been feeling in the last week, expressed as common symptoms of anxiety (such as numbness and tingling, sweating not due to heat, and fear of the worst happening). This inventory was designed to minimize the overlap with depression scales (Beck et al-1988).The BAI has a maximum score of 63. The standardized cutoffs for anxiety severity are: 0-7: minimal level of anxiety 8-15: mild anxiety 16-25: moderate anxiety 26-63: severe anxiety
Time frame: Week 26
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Beck Anxiety Inventory (BAI) Score | 3.3 score | Standard Error 0.5 |
| Gabapentin Enacarbil | Beck Anxiety Inventory (BAI) Score | 4.6 score | Standard Error 0.4 |
Beck Depression Inventory - II
The BDI-II is a 21-item multiple choice questionnaire that is used for measuring the severity of depression (Beck et al-1966). Each item is scored on a scale value of 0 to 3. The standardized cutoffs for depression severity are: 0-13: minimal depression 14-19: mild depression 20-28: moderate depression 29-63: severe depression
Time frame: Week 26
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Beck Depression Inventory - II | 5.2 score | Standard Error 0.5 |
| Gabapentin Enacarbil | Beck Depression Inventory - II | 6.5 score | Standard Error 0.5 |
Cigarettes Per Week Among Smokers
A quantity frequency interview of three questions to assess cigarette smoking behavior and other tobacco/nicotine containing products use during the study: 1) Over the past week, on how many days did you smoke cigarettes?, 2) On the days you smoked during the past week, how many cigarettes did you smoke on average?, and 3) Have you used any other tobacco or nicotine containing products besides cigarettes in the past week (e.g., cigars, cigarellos, pipes, bidis, or smokeless tobacco such as pan, chewing tobacco, or snuff, or nicotine replacement therapies such as patch or gum)?.
Time frame: Weeks 22-25
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Cigarettes Per Week Among Smokers | 61.4 cigarettes per week | Standard Error 8.3 |
| Gabapentin Enacarbil | Cigarettes Per Week Among Smokers | 71 cigarettes per week | Standard Error 8.3 |
Percentage of Days Abstinent Per Week
Timeline Follow Back daily drinking data used to calculate the % of days abstinent per week.
Time frame: Weeks 22-25
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Percentage of Days Abstinent Per Week | 49 percentage of days | Standard Error 3.9 |
| Gabapentin Enacarbil | Percentage of Days Abstinent Per Week | 49.3 percentage of days | Standard Error 3.9 |
Percentage of Heavy Drinking Days Per Week
Timeline Follow Back data used to calculate the % of heavy drinking days per week. Heavy drinking is 4+ drinks per day for females and 5+ drinks per day for males
Time frame: Weeks 22-25
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Percentage of Heavy Drinking Days Per Week | 46.5 percentage of days | Standard Error 4.2 |
| Gabapentin Enacarbil | Percentage of Heavy Drinking Days Per Week | 43.1 percentage of days | Standard Error 4.1 |
Percentage of Subjects Abstinent From Alcohol (Key Secondary Endpoint)
Timeline Follow-back drinking data is used to calculate the % of subjects that report not drinking alcohol during weeks 22-25
Time frame: Weeks 22-25
Population: no imputation was performed so the number analyzed is reduced
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Sugar Pill | Percentage of Subjects Abstinent From Alcohol (Key Secondary Endpoint) | 16 Participants |
| Gabapentin Enacarbil | Percentage of Subjects Abstinent From Alcohol (Key Secondary Endpoint) | 17 Participants |
Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 1-level
Timeline Follow Back data is used to calculate the % of participants that decrease at least 1-level WHO drinking risk category. The WHO has developed a drinking risk categorical scale that can be used in a responder analysis approach to assess clinically relevant decreases in alcohol consumption (Aubin et al-2015). The WHO 1- and 2-level decrease endpoints are the percentage of subjects experiencing at least 1- and 2-level decrease in WHO levels of alcohol consumption, respectively, from the level at baseline (the period including the 28 days before screening) to the level during the last 4 weeks of the maintenance phase (Study Weeks 22-25). The WHO levels are as follows: Males Females Low Risk 1 to 40g 1 to 20g Medium Risk 41 to 60g 21 to 40g High Risk 61 to 100g 41 to 60g Very High Risk 101+g 61+g
Time frame: Weeks 22-25
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Sugar Pill | Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 1-level | 107 Participants |
| Gabapentin Enacarbil | Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 1-level | 115 Participants |
Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 2-levels
Timeline Follow Back data is used to calculate the % of participants that decrease at least 1-level WHO drinking risk category. The WHO has developed a drinking risk categorical scale that can be used in a responder analysis approach to assess clinically relevant decreases in alcohol consumption (Aubin et al-2015). The WHO 1- and 2-level decrease endpoints are the percentage of subjects experiencing at least 1- and 2-level decrease in WHO levels of alcohol consumption, respectively, from the level at baseline (the period including the 28 days before screening) to the level during the last 4 weeks of the maintenance phase (Study Weeks 22-25). The WHO levels are as follows: Males Females Low Risk 1 to 40g 1 to 20g Medium Risk 41 to 60g 21 to 40g High Risk 61 to 100g 41 to 60g Very High Risk 101+g 61+g
Time frame: Weeks 22-25
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Sugar Pill | Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 2-levels | 69 Participants |
| Gabapentin Enacarbil | Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 2-levels | 80 Participants |
Pittsburgh Sleep Quality Index (PSQI) Score
The PSQI is a 19-item questionnaire assessing the subject's overall sleep experience in the past 30 days (Buysse et al-1989). The lower the overall score, the better the person sleeps. The tool has an adequate internal reliability, validity and consistency for clinical and community samples of the various populations. Range is (0-21); \>6 indicative of poor sleep quality.
Time frame: Week 26
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Pittsburgh Sleep Quality Index (PSQI) Score | 4.4 score | Standard Error 0.2 |
| Gabapentin Enacarbil | Pittsburgh Sleep Quality Index (PSQI) Score | 4.9 score | Standard Error 0.2 |
Weekly Mean Drinks Per Drinking Day
Timeline Follow Back daily drinking data used to calculate the weekly mean drinks per drinking day
Time frame: Weeks 22-25
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Weekly Mean Drinks Per Drinking Day | 3.9 drinks per drinking day | Standard Error 0.4 |
| Gabapentin Enacarbil | Weekly Mean Drinks Per Drinking Day | 4.1 drinks per drinking day | Standard Error 0.4 |
Weekly Mean Number of Drinks Per Week
Timeline Follow Back data used to calculate the weekly mean number of drinks per week
Time frame: Weeks 22-25
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Weekly Mean Number of Drinks Per Week | 21.4 drinks per week | Standard Error 2.4 |
| Gabapentin Enacarbil | Weekly Mean Number of Drinks Per Week | 23.1 drinks per week | Standard Error 2.3 |